MétaCan
Menu
Back to cohort
Record W4385973055 · doi:10.1016/j.jtocrr.2023.100562

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies

2023· article· en· W4385973055 on OpenAlexafffundabout
Sally C.M. Lau, Kirstin Perdrizet, Andrea S. Fung, Danilo Giffoni M. M. Mata, Jessica Weiss, Nick Holzapfel, Geoffrey Liu, Penelope A. Bradbury, Frances A. Shepherd, Adrian G. Sacher, Harriet Feilotter, Brandon S. Sheffield, David Hwang, Ming‐Sound Tsao, Susanna Y. Cheng, Parneet Cheema, Natasha B. Leighl

Bibliographic record

VenueJTO Clinical and Research Reports · 2023
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsHealth Sciences CentreSunnybrook Health Science CentreKingston Health Sciences CentreWilliam Osler Health SystemQueen's UniversityBrampton Civic HospitalPrincess Margaret Cancer CentreUniversity of TorontoUniversity Health Network
FundersNational Cancer InstituteCanadian Institutes of Health ResearchEMD SeronoGenentechIncyteCanadian Cancer Society Research InstituteHelsinnBeiGeneMerck KGaAPrincess Margaret Cancer FoundationSanofiGlaxoSmithKlineAmgenPfizerAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsMedicineInternal medicineOncologyToxicityTargeted therapyCancer

Abstract

fetched live from OpenAlex

Introduction NSCLC with MET exon 14 skipping mutation ( MET ex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore, sought to characterize the treatment patterns, outcomes, and emerging issues of treatment sequencing in patients with MET ex14-mutant NSCLC. Methods We reviewed all NSCLC cases with MET ex14 alterations between 2014 and 2020 across four Canadian cancer centers. Demographics, disease characteristics, systemic therapy, overall response rates (ORRs), survival, and toxicity were summarized. Results Among 64 patients with MET ex14-mutant NSCLC, the median overall survival was 23.1 months: 127.0 months in stage 1, 27.3 months in resected stage 2 and 3, and 16.6 months in unresectable stage 3 or 4 disease, respectively. In patients with advanced disease, 22% were too unwell for systemic treatment. MET tyrosine kinase inhibitors (TKIs) were administered to 28 patients with an ORR of 33%, median progression-free survival of 2.7 months, and 3.8 months for selective TKIs. Programmed cell death protein-1 (PD-1) inhibitors were given to 25 patients—the ORR was 44% and progression-free survival was 10.6 months. No responses were seen with subsequent MET TKIs after initial TKI treatment. Grade 3 or higher toxicities occurred in 64% of patients who received MET TKI after PD-1 inhibitors versus 8% in those who did not receive PD-1 inhibitors. Conclusions Many patients with advanced MET ex14 NSCLC were too unwell to receive treatment. PD-1 inhibitors seem effective as an initial treatment, although greater toxicity was seen with subsequent MET TKIs. Thus, timely testing for MET ex14 skipping and initial therapy are imperative to improving patient survival.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.192
Threshold uncertainty score0.405

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.097
GPT teacher head0.459
Teacher spread0.362 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueJTO Clinical and Research ReportsSame topicLung Cancer Treatments and MutationsFrench-language works237,207